Evidence map›Paper›PMID 35598995›Full record

ArticleInternal medicine (Tokyo, Japan)2022

Prognosis Prediction Using Magnetic Resonance Spectroscopy and Oligoclonal Bands in Central Nervous System Methotrexate-associated Lymphoproliferative Disorder.

Hiroki Ueno, Narumi Ohno, Takafumi Abe, Kazuki Kimoto, Chika Matsuoka, Mayumi Giga, Hiroyuki Naito, Tomoyuki Kono, Miyuki Takasu, Naoya Kidani and 3 more

Open access · diamondAbstract read
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Hiroki UenoDepartment of Neurology, Hiroshima City Hiroshima Citizens Hospital, Japan.
Narumi OhnoDepartment of Neurology, Hiroshima City Hiroshima Citizens Hospital, Japan.
Takafumi AbeDepartment of Neurology, Hiroshima City Hiroshima Citizens Hospital, Japan.
Kazuki KimotoDepartment of Neurology, Hiroshima City Hiroshima Citizens Hospital, Japan.
Chika MatsuokaDepartment of Neurology, Hiroshima City Hiroshima Citizens Hospital, Japan.
Mayumi GigaDepartment of Neurology, Hiroshima City Hiroshima Citizens Hospital, Japan.
Hiroyuki NaitoDepartment of Neurology, Hiroshima City Hiroshima Citizens Hospital, Japan.
Tomoyuki KonoDepartment of Neurology, Hiroshima City Hiroshima Citizens Hospital, Japan.
Miyuki TakasuDepartment of Radiology, Hiroshima City Hiroshima Citizens Hospital, Japan.
Naoya KidaniDepartment of Neurosurgery and Neuroendovascular Surgery, Hiroshima City Hiroshima Citizens Hospital, Japan.
Rie YamasakiDepartment of Pathology, Hiroshima City Hiroshima Citizens Hospital, Japan.
Koichi IchimuraDepartment of Pathology, Hiroshima City Hiroshima Citizens Hospital, Japan.
Eiichi NomuraDepartment of Neurology, Hiroshima City Hiroshima Citizens Hospital, Japan.
Hiroshima City Asa Citizens Hospital · JPOkayama University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Central nervous system methotrexate-associated lymphoproliferative disorder (CNS-MTX-LPD) is rare, but its spontaneous regression has been observed in some patients after withdrawal of agents. We herein report three cases of primary CNS-MTX-LPD that received oral MTX for rheumatoid arthritis. Epstein-Barr virus and oligoclonal bands (OCBs) were positive, while proton magnetic resonance spectroscopy (

Indexed as

Antirheumatic AgentsEpstein-Barr Virus InfectionsLymphoproliferative DisordersCentral Nervous SystemHerpesvirus 4, HumanHumansMagnetic Resonance SpectroscopyMethotrexateOligoclonal BandsPrognosisAntirheumatic AgentsMethotrexateOligoclonal BandsEBVmethotrexate-associated lymphoproliferative disorderMRSoligoclonal bands

Identifiers

PMID35598995
PMCPMC9841117
OpenAlexW4282924654

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.